Peer-reviewed veterinary case report
Toxicity of every-other-day cyclophosphamide chemo in dogs with cancer
By Matsuyama, Arata et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2017·Department of Biomedical Sciences (Matsuyama, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer.
- Species:
- dog
Plain-English summary
A group of dogs with cancer were treated with a chemotherapy drug called metronomic cyclophosphamide, given every other day. Unfortunately, nearly half of the dogs experienced side effects, with 32% developing a painful bladder condition known as sterile hemorrhagic cystitis after about four months of treatment. The risk of this bladder issue increased with higher doses of the medication. This study suggests that if your dog is on this chemotherapy, your vet should closely monitor them and consider preventive treatments to help avoid complications.
People also search for: dog cancer treatment side effects · metronomic cyclophosphamide bladder problems · sterile hemorrhagic cystitis in dogs
Abstract
Sterile hemorrhagic cystitis (SHC) is an important complication of cyclophosphamide chemotherapy in dogs as it is reported in up to 23% of cases with various protocols. The current study reports toxicities of a protocol of metronomic cyclophosphamide, and identifies risk factors for development of adverse effects. A retrospective cohort study of dogs treated with metronomic cyclophosphamide at an intended dose of 25 mg/mevery other day was conducted. Fifty dogs were included with a median length of treatment of 90 days (range: 1 to 1305 days). Treatment was discontinued in 22 dogs (44%) due to adverse effects; 16 dogs (32%) developed SHC after a median time of 127.5 days (range: 54 to 1305 days). Higher cumulative dose was significantly associated with a higher risk of SHC development (= 0.048). Therefore, close monitoring and/or prophylactic treatments should be considered for patients receiving chronic metronomic cyclophosphamide therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28042155/